
Onyx explores possible sale after rejecting Amgen offer
NEW YORK (Reuters) - Cancer drugmaker Onyx Pharmaceuticals Inc said on Sunday it rejected a roughly $10 billion takeover offer from larger biotechnology company Amgen Inc as too low but...
eNewspaper
Trending:









